MaxCyte (NASDAQ:MXCT – Get Free Report) is scheduled to post its quarterly earnings results after the market closes on Tuesday, May 7th. Analysts expect MaxCyte to post earnings of ($0.14) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.
MaxCyte (NASDAQ:MXCT – Get Free Report) last announced its quarterly earnings results on Tuesday, March 12th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. MaxCyte had a negative return on equity of 15.90% and a negative net margin of 91.85%. The company had revenue of $15.67 million during the quarter, compared to analysts’ expectations of $15.60 million. On average, analysts expect MaxCyte to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
MaxCyte Stock Performance
Shares of MXCT opened at $3.77 on Monday. MaxCyte has a 52 week low of $2.45 and a 52 week high of $5.55. The stock has a market capitalization of $394.12 million, a price-to-earnings ratio of -10.19 and a beta of 1.36. The stock has a fifty day moving average of $4.13 and a 200-day moving average of $4.36.
Analysts Set New Price Targets
Get Our Latest Analysis on MaxCyte
MaxCyte Company Profile
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Featured Articles
- Five stocks we like better than MaxCyte
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 4/29 – 5/3
- What is the Nikkei 225 index?
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- The How and Why of Investing in Biotech Stocks
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.